News
Fifth CIIE holds seminar on rare diseases Release date： 2022-05-18 Source：China International Import Expo Bureau
An online seminar on rare diseases was held on May 12 by the China International Import Expo Bureau, the National Exhibition and Convention Center (Shanghai), and the medicine special committee of the CIIE Enterprise Alliance.
Several Chinese government departments involved in the sectors of health, science and technology, medical products and healthcare security have implemented multiple measures over the past decade, such as making a list of rare diseases and establishing a treatment cooperation network of hospitals, to help the patients, said Liu Fuxue, deputy director-general of the CIIE Bureau.
The CIIE is dedicated to building a platform to facilitate exchange and cooperation between different parties and promoting innovation in this sector, Liu added.
The National Health Commission said it hopes governments, medical institutions and companies can intensify efforts in the research and development of drugs for rare diseases and establish a complete system to prevent and treat such diseases.
According to senior executives from Takeda, Novartis, Pfizer and Sanofi, all of which are members of the medicine special committee of the CIIE Enterprise Alliance, the annual import expo has helped accelerate the approval process and market entry of many of their products.
Representatives from the Shanghai Municipal Healthcare Security Administration, the Illness Challenge Foundation, and medical companies also had discussions about improving the accessibility of drugs for rare diseases during the seminar.
By Zhao Luyang
The China International Import Expo Bureau (hereinafter referred to as the "CIIE Bureau") cites or reposts media reports for non-commercial purposes to facilitate information sharing. Such actions do not constitute an endorsement of the accuracy, authenticity, or legality of the original content, nor do they reflect the official stance of the CIIE Bureau. All copyrights and legal responsibilities for the reposted content remain with the original publishers and authors.
If any individual or entity believes that content shared on this website infringes their legitimate rights and interests, please promptly notify us in writing, providing detailed explanations, supporting documentation, and rationale. Upon receiving such materials, we will promptly remove or rectify the disputed content or take other appropriate measures.
Reposted or cited information may be time-sensitive. Users are advised to exercise independent judgment regarding the accuracy and completeness of the content. The CIIE Bureau shall not be liable for any direct, indirect, incidental, consequential, special, punitive, or exemplary damages arising from the use of or inability to use the information or links provided on this website.。
The CIIE Bureau respects intellectual property rights and is committed to delivering high-quality content services within a lawful and compliant framework.